Global NewsNews

Boston-based MedTherapy plans to reduce manufacturing cost, time of CAR-T cancer gene therapies

The technology is being developed to manufacture CAR-T cells cancer gene therapy in a few days 

Boston-based MedTherapy Biotechnology, a privately held CAR-T cell cancer gene therapy biotechnology company, announced that its technology could potentially reduce the time and cost to manufacture CAR-T cell cancer gene therapy to a fraction, approximately by 70 per cent.

Its clinical development plan and strategies are being presented at the BIOTECH SHOWCASE conference being held during the JPMorgan Chase Healthcare Conference in San Francisco, CA.

“MedTherapy was founded with a mission to make the exorbitantly expensive CAR-T cell cancer gene therapy more affordable and accessible. We are pleased to announce that our strategies have finally made this vision a reality,” said Bikash Verma, CEO, MedTherapy Biotechnology. “While CAR-T cell gene therapy for cancer has proven itself to be a miraculous life-saving therapy, however, its current exorbitant cost renders it unaffordable for many patients in the US and virtually all patients in developing countries. Together with our US and global partners, we are trying to change that paradigm by developing an integrated strategy for the next generation CAR-T cell therapy and manufacturing processes to dramatically reduce its cost.”

CAR-T therapy is plagued by several constraints responsible for its exorbitant cost and complex manufacturing processes, viz. four to six weeks to manufacture; industry-wide lack of capacity to scale up manufacturing; acute shortage of most critical raw material, the viral vectors; and patients relapsing after being administered CAR-T cell therapy. While there has been lots of focus upon increasing its efficacy, not commensurate attention has been paid to making it affordable and accessible globally. That would necessitate significant innovation of the processes, virus vectors, and scaling up production, collectively.

Thus, instead of being singularly focussed upon only the clinical development of CAR-T cell therapy, MedTherapy has developed an integrated approach by building three complementary strategies and infrastructures to overcome the current existential constraints: to develop next generation of more efficient CAR-T therapy candidates; a global GMP grade commercial manufacturing facility with cost and time-efficient technologies; and next-generation virus vector technology and facilities for large scale industry level manufacturing of viral vector which is the most critical raw material and the most expensive. Together, the integrated and innovative approaches lead to a dramatic reduction in the cost and time to manufacture, and thus the reduced cost of CAR-T cell gene therapy.

The technology is being developed to manufacture CAR-T cells cancer gene therapy in a few days instead of the industry average of four to six weeks. And, at dramatically reduced costs.

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Back to top button
Close
Close